Medicare AdvantagePrior AuthMedium impact
Kuvan® (sapropterin) (Revised)
Humana·Endocrinology, Pediatrics, Pharmacy +1 more·Medicare Advantage
Effective date
Jan 1, 2022
We identified it
Jul 22, 2026
Summary
This is a revised Medicare Advantage prior authorization policy for Kuvan® (sapropterin) and its generics/brand equivalents used to treat phenylketonuria (PKU). The policy requires prior authorization and specifies that brand Kuvan requests require documentation of previous treatment, contraindication, or intolerance to generic sapropterin. The revision date of July 22, 2026 indicates recent updates to this existing policy.
Action Required
Immediately: Billing team must ensure all Kuvan® (sapropterin) claims—including brand names Kuvan, Javygtor, and Zelvysia, as well as generic sapropterin in oral powder packet and soluble tablet forms—are submitted with prior authorization. For brand Kuvan requests specifically, obtain and attach documentation proving the member has had previous treatment with generic sapropterin, a documented contraindication, or documented intolerance to generic sapropterin. Update pharmacy billing system to require this documentation field for brand requests. Route all Kuvan requests through the prior authorization workflow before claim submission. Claims submitted without prior authorization or without required contraindication/intolerance documentation for brand requests will be denied by Humana Medicare Advantage plans.